PALATIN TECHNOLOGIES INC — Investor Relations & Filings

Palatin Technologies Inc. is a biopharmaceutical company focused on discovering and developing novel therapeutics. The company leverages deep expertise in receptor pharmacology and peptide/small-molecule design to modulate the melanocortin receptor (MCR) system. This system plays a crucial role in regulating appetite, energy homeostasis, inflammation, and immune response. Palatin's approach involves developing highly selective melanocortin agonists, targeting specific receptor subtypes like MC1R and MC4R, to address complex, multifactorial diseases. Their primary therapeutic areas include obesity, with a particular emphasis on rare neuroendocrine disorders such as hypothalamic obesity and Prader-Willi syndrome, as well as various inflammatory and autoimmune conditions. Palatin aims to develop first-in-class medicines to meet significant unmet medical needs.